Skip to main content

NGM Biopharmaceuticals Inc

NGMDelisted Apr 5, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001426332

NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding NGM Biopharmaceuticals Inc changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of NGM: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders108107−1
Shares43.0M43.1M+52.5K (+0.1%)
Value$1.25B$849.7M−$401.2M (−32.1%)

New holders (18)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to NGM in Q2 2021
InstitutionSharesValue% of portfolio
BVF Inc955,000$18.8M0.71%
Boxer Capital, LLC500,000$9.86M0.35%
AXA S.A.292,441$5.77M0.02%
Lord, Abbett & Co. LLC189,101$3.73M0.01%
HRT Financial LP97,313$1.92M0.02%
Swiss National Bank67,600$1.33M0.00%
PDT Partners, LLC36,200$714.0K0.05%
Ergoteles LLC31,200$615.0K0.01%
Schonfeld Strategic Advisors LLC30,253$597.0K0.01%
Millennium Management LLC21,501$424.0K0.00%
Stifel Financial Corp17,550$346.0K0.00%
Credit Suisse AG14,813$292.0K0.00%
Susquehanna International Group, LLP14,047$277.0K0.00%
UBS Asset Management Americas Inc10,191$201.0K0.00%
Federated Hermes, Inc.6,678$132.0K0.00%
Acadian Asset Management LLC4,305$85.0K0.00%
Private Capital Group, LLC91$2.00K0.00%
Berman Capital Advisors, LLC57$1.00K0.00%

Sold out (19)

Institutions that held NGM Biopharmaceuticals Inc at the end of Q1 2021 and filed for Q2 2021 without it.